WO2006101119A1 - Promoteur de synthese du collagene - Google Patents

Promoteur de synthese du collagene Download PDF

Info

Publication number
WO2006101119A1
WO2006101119A1 PCT/JP2006/305693 JP2006305693W WO2006101119A1 WO 2006101119 A1 WO2006101119 A1 WO 2006101119A1 JP 2006305693 W JP2006305693 W JP 2006305693W WO 2006101119 A1 WO2006101119 A1 WO 2006101119A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
collagen synthesis
skin
synthesis promoter
extract
Prior art date
Application number
PCT/JP2006/305693
Other languages
English (en)
Japanese (ja)
Inventor
Masami Tachikawa
Fumito Karakida
Zenji Kawakami
Daisuke Matsuura
Hirotoshi Kanatani
Original Assignee
Tsumura & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura & Co. filed Critical Tsumura & Co.
Publication of WO2006101119A1 publication Critical patent/WO2006101119A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a collagen synthesis promoter, and more specifically, a collagen synthesis promoter aimed at promoting collagen synthesis in fibroblasts, imparting freshness and firmness to the skin, and maintaining the water retaining ability of the epidermis. About.
  • Collagen is the main protein that forms the binding thread and weave of animals. Collagen occupies nearly 30% of the total protein of the human body. In the skin, collagen has a function of imparting freshness, thickness and thickness to the skin, retaining the water retaining ability of the epidermis, and retaining the elasticity of the skin. However, due to internal factors such as aging and external factors such as ultraviolet rays and active oxygen, the softness and moisturizing power of the skin decline, leading to aging phenomena such as wrinkles and sagging.
  • collagen is known to play an important role in the suppression and recovery of skin aging phenomenon.
  • a composition containing collagen or the synthesis of collagen is known.
  • a method of applying a composition containing a substance that promotes skin to the skin has been performed.
  • Ascorbic acid phosphate, retinoic acid, and the like are known as substances that promote collagen synthesis.
  • Ascorbic acid phosphate is a type of ascorbic acid derivative that is converted to vitamin C by transdermal absorption.
  • Vitamin C is one of the cell growth factors that induces the formation of cells by maturing the intercellular substances (extracellular matrix) with a collagen skeleton that only activates collagen synthesis. It has been clarified by an experiment of cell culture using ascorbic acid-2-phosphate Mg salt (APM) (see Non-Patent Document 1).
  • Retinoic acid is a derivative of vitamin A, and its physiological activity is about 300 times that of vitamin A. It is the body of biological activity of vitamin A in the body itself. In the United States, it has been approved by the FDA (Food and Drug Administration) as a therapeutic drug for skin and acne.
  • Non-Patent Document 2 reports that an alcohol extract of leaves of milobaran (Terminalia chebula) has an effect on wound healing. In an in vivo test using rats, It significantly promoted epithelialization, and a significant increase in protein, DNA and collagen components in the granulation and weaving was observed. It has been reported that the leaf power of milobaran has been isolated from keblagic acid, kebric acid, corilagin, and gallic acid (see Non-Patent Document 3).
  • Non-patent literature l Eur. J. Biochem, 174, p231 (1988)
  • Non-Patent Document 2 Phytother.Res, 16, p227 (2002)
  • Non-Patent Document 3 Bull.Central Leather Res.Inst., 8, p230 (1961)
  • the method of applying collagen to the skin surface to supply collagen to the skin does not essentially improve skin function because collagen has a high molecular structure and is not absorbed by the barrier function of the epidermis. I helped. Further, collagen synthesis promoting substances such as retinoic acid are desired to be further improved rather than being sufficiently satisfactory in terms of effects.
  • an object of the present invention is to provide a collagen synthesis promoter having a sufficient collagen synthesis promoting action and a high skin conditioning effect.
  • the collagen synthesis promoter of the present invention is characterized by comprising an active ingredient of an extract of fruit of milobaran (hereinafter also referred to as “mylobaran fruit extract”).
  • mylobaran fruit extract an extract of fruit of milobaran
  • the alcoholic extract of milobaran leaves has a wound healing effect and significantly increases the amount of collagen in the granulation tissue.
  • the extract of milobaran fruit is effective in promoting collagen.
  • the degree of the collagen synthesis promoting action of myrobalan leaf the details are unknown and it is difficult to obtain.
  • Milova None of the substances contained in the orchid leaf extract was known as to which substances contribute more to collagen synthesis.
  • the other collagen synthesis promoter of the present invention is one or more selected from the group consisting of chebulagic acid, chebulinic acid, gallic acid and corilagin. It is characterized by containing two or more active ingredients.
  • the collagen synthesis promoter of the present invention can be suitably used as an external preparation for skin, and can be suitably used as a skin quality improving agent for use.
  • the collagen synthesis promoter of the present invention can effectively promote the synthesis of collagen.
  • the collagen synthesis promoter of the present invention is used as an external preparation for skin, it is possible to give the skin freshness, texture, texture, and to maintain the water retaining ability of the epidermis.
  • FIG. 1 (a) A micrograph of the skin when a topical skin preparation containing milobalan fruit cocoon kiss is used, and (b) is a micrograph of the skin when only the base is applied.
  • the collagen synthesis promoter of the present invention contains a milobaran fruit extract as an active ingredient, but a milobaran fruit extract can be obtained by a conventional method.
  • the milobaran fruit is soaked or heated under reflux with an extraction solvent. Then, it is filtered, and the resulting extract can be obtained as it is or by concentrating it.
  • the concentrated or dried extract can be dissolved in a solvent and used again.
  • the extraction solvent any solvent that is usually used for extraction can be used, and examples thereof include water and organic solvents such as ethanol, 1,3-butylene glycol, propylene glycol, acetone, methanol, and ethyl acetate.
  • the other collagen synthesis promoter of the present invention comprises one or more active ingredients selected from the group consisting of keblagic acid, kebric acid, gallic acid and corilagin, which are components contained in the milobaran fruit extract.
  • keblagic acid and kevulinic acid that exhibit a high collagen synthesis promoting action and have a high content are used.
  • Each component can be obtained by extracting and isolating plant power or synthesizing by a known method.
  • the fruit strength of milobaran can be suitably obtained by extracting the milobaran fruit extract and then isolating it by the above method.
  • the isolation method is not particularly limited, but it can be suitably isolated by techniques such as liquid-liquid distribution, various chromatographies, and recrystallization.
  • Each of the components contained in the thus-obtained milobaran fruit extract and milobaran fruit extract has an excellent collagen synthesis promoting action.
  • the collagen synthesis promoter of the present invention can be used in various fields such as pharmaceuticals, quasi drugs, foods and cosmetics.
  • the collagen synthesis promoter of the present invention is used as a skin external preparation
  • the compounding amount of milobalan fruit extract and the components of kerobic acid, kebric acid, gallic acid and corilagin, which are the components of myrobalan fruit extract is usually preferably 0.0001 to 5% as a dry weight and more preferably 0.001 to 0.1% as a total weight in the total amount of the external preparation. Below this range, the effect of promoting collagen synthesis is hard to be fully exerted.If the content exceeds this range, the effect cannot be expected to increase, and it is not economical. This is preferable because of problems such as dyeing with crude drugs!
  • the skin external preparation of the present invention includes, in addition to the above-mentioned myrobalan fruit extract, other components that are usually used in skin external preparations such as cosmetics and pharmaceuticals within the range not impairing the effects of the present invention, for example, Moisturizer, oil component, surfactant, vitamins, proteolytic enzyme, thickener, preservative, powder, antioxidant, ultraviolet absorber, emulsifier, alcohol, color material, aqueous component, water, various A skin nutrient or the like can be appropriately blended as necessary.
  • other components that are usually used in skin external preparations such as cosmetics and pharmaceuticals within the range not impairing the effects of the present invention, for example, Moisturizer, oil component, surfactant, vitamins, proteolytic enzyme, thickener, preservative, powder, antioxidant, ultraviolet absorber, emulsifier, alcohol, color material, aqueous component, water, various A skin nutrient or the like can be appropriately blended as necessary.
  • humectant examples include polyhydric alcohols such as glycerin, propylene glycol, polyethylene glycol and 1,3 butylene glycol, sugar alcohols such as sorbit and mannitol, hyaluronate, chondroitin sulfate, chitosan and the like.
  • oils component examples include natural fats and oils such as soybean oil, nuka oil, apogado oil, almond oil, olive oil, cacao butter, sesame oil, persic oil, castor oil, coconut oil, mink oil, beef tallow, and lard. Hardened oils obtained by hydrogenation of these natural fats and oils, synthetic glycerides such as myristic acid glyceride, 2-ethylhexanoic acid glyceride, fats and oils such as diglyceride, jojoba oil, carnauba wax, whale wax, beeswax, lanolin, etc.
  • natural fats and oils such as soybean oil, nuka oil, apogado oil, almond oil, olive oil, cacao butter, sesame oil, persic oil, castor oil, coconut oil, mink oil, beef tallow, and lard.
  • Hardened oils obtained by hydrogenation of these natural fats and oils synthetic glycerides such as myristic acid glyceride, 2-
  • Waxes liquid paraffin, petrolatum, paraffin, microcrystalline wax, hydrocarbons such as ceresin, squalane, pristane, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid Higher fatty acids such as lanolinic acid and isostearic acid, lauryl alcohol monole, Higher alcohols such as cetinoleanoreconole, stearinoreanoreconole, oleinoleanoreconole, cholesterol, 2-hexyldecanol, jojoba alcohol, cetyl octanoate, myristyl lactate, cetyl lactate, myristic acid Examples include myristyl, octyldodecyl myristate, isopropyl myristate, isopropyl palmitate, isopropyl adipate, buty
  • surfactant examples include glycerin fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, tetraoleic acid polyoxyethylene sorbite, polyoxyethylene alkyl ether, Polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene castor oil, polyglycerin fatty acid ester, fatty acid monodalide, sucrose fatty acid ester, higher fatty acid al
  • Nonionic surfactants such as strength olamide, sodium a-olefin sulfonate, sodium lauryl sulfate, sodium cetyl sulfate, poly Sodium xylethylene lauryl sulfate, sulfosuccinic acid Sodium lauryl sulfonate, linear
  • Vitamins include, for example, vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin F, vitamin, vitamin P, vitamin U, carcin, ferulic acid, ⁇ -oryzanol, lipo
  • examples include acids, orotic acid and derivatives thereof.
  • the proteolytic enzyme include pepsin, trypsin, chymotrypsin, cathebcin, papain, bromelain, ficin, and bacteria, yeast, and mold-derived proteases.
  • Examples of the thickener include water-soluble polymer compounds such as carboxybule polymer, carboxymethylcellulose, polybulal alcohol, carrageenan, gelatin, xanthan gum, polyacrylate, and sodium chloride and potassium salt.
  • An inorganic salt is mentioned.
  • Examples of the preservative include phenoxyethanol, methyl paraben, ethyl paraben, butyparaben, sodium benzoate and the like.
  • powders include talc, sericite, my strength, kaolin, silica, bentonite, vermiculite, zinc white, mica, mica titanium, titanium oxide, magnesium oxide, zirconium oxide, barium sulfate, bengara, iron oxide, Examples include ultramarine blue.
  • Other ingredients include fragrances, pigments, fungicides and the like.
  • the dosage form of the external preparation for skin of the present invention is arbitrary.
  • it can be made into a lotion, a milk, a cream, an ointment, a dispersion, a gel, an aerosol, a nose, a bath, and the like. it can.
  • Human fibroblasts (Detroit551) were cultured in MEM medium containing 10% FBS, 1% NEAA, lmmol / L sodium pyruvate under conditions of 37 ° C, 5% CO-95% air.
  • the cells were cultured for 3 days under 2 ir conditions.
  • the samples are, as examples, myrobalan fruit extract (Example 1), keblagic acid (Example 2), gallic acid (Example 3), and kerblic acid (Example 3), which are the main components of myrobalan fruit extract. 4) and corilagin (Example 5), as a comparative example, quebrin, as a reference example, L-ascorbic acid 2-phosphate ester Mg salt (APM), retinoic acid, which is known to have a conventional ability to promote collagen synthesis, Each sample was adjusted to a concentration of 25, 50, lOOppm and used.
  • APM L-ascorbic acid 2-phosphate ester Mg salt
  • Kebric acid 1 160.7 ⁇ 55.0 "521.7 ⁇ 35.8” 495.0 ⁇ 32.0 "4
  • Kebranin 1 1 1.9 ⁇ 9.1 58.1 ⁇ 28.2 140.6 ⁇ 18.4 1
  • a cream formulation containing 0.5% milobaran fruit extract (hereinafter referred to as “Milobalan formulation”). A cream ", u) was prepared.
  • a powder bath containing milobaran fruit extract was prepared by uniformly mixing all raw materials.
  • the alcohol phase is added to the aqueous phase to prepare a stock solution, the stock solution is put into a can, and filled with a gas such as LPG or butane. Aerosol product) was prepared.
  • the oil phase and the aqueous phase were each heated to 70 ° C for complete dissolution.
  • the oil phase was added to the aqueous phase to emulsify, and after cooling, the added phase was added to prepare a body cream containing a myloparan fruit extract with pH 6.1.
  • Tri cabril 'cabric acid
  • the oil phase and the aqueous phase were each heated to 70 ° C to be completely dissolved.
  • An oil phase was added to the aqueous phase to emulsify, and after cooling, a finely pulverized powder phase and an additional phase were added to prepare a sunscreen tarm containing SPF20 milobaran fruit extract.
  • Titanium oxide ⁇ Keyed anhydride composite 2.0
  • the skin gloss, firmness, softness, crispness, dullness, texture and wrinkle before and after application for 1 month were evaluated according to the following evaluation criteria.
  • Fig. 1 shows the results of micrographs after application for 1 month.
  • A shows the case where a topical skin preparation containing milobalan fruit juice is applied
  • (b) shows the case where only the base is applied. From the photograph, it can be seen that the texture is better when using a topical skin preparation containing a milobaran fruit extract compared to the base alone. In addition, moisturizing power and elasticity improved, and dullness disappeared.

Abstract

L’invention concerne un promoteur de synthèse du collagène capable de présenter une activité de promotion de la synthèse du collagène satisfaisante et un haut pouvoir de conditionnement cutané. Elle concerne un promoteur de synthèse du collagène comprenant, en tant que principe actif, un extrait du fruit de myrobalan, et concerne un promoteur de synthèse du collagène comprenant, en tant que principe actif, un ou deux ou davantage d’éléments choisis dans le groupe constitué par l’acide chébulagique, l’acide chébulinique, l’acide gallique et la corilagine. Le promoteur de synthèse du collagène concerné est approprié à une utilisation en tant que préparation externe cutanée ou agent améliorant la qualité de la peau ; et peut conférer une humidité et une souplesse à la peau, peut effectuer un conditionnement de la texture et peut soutenir le pouvoir de rétention de l’eau de l’épiderme.
PCT/JP2006/305693 2005-03-22 2006-03-22 Promoteur de synthese du collagene WO2006101119A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-082030 2005-03-22
JP2005082030A JP2006265120A (ja) 2005-03-22 2005-03-22 コラーゲン合成促進剤

Publications (1)

Publication Number Publication Date
WO2006101119A1 true WO2006101119A1 (fr) 2006-09-28

Family

ID=37023779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/305693 WO2006101119A1 (fr) 2005-03-22 2006-03-22 Promoteur de synthese du collagene

Country Status (2)

Country Link
JP (1) JP2006265120A (fr)
WO (1) WO2006101119A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100031346A1 (it) * 2021-12-14 2023-06-14 Giuliani Spa Composizione ad attivita’ antinvecchiamento della pelle

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008143784A (ja) * 2006-12-06 2008-06-26 B & C Laboratories Inc 細胞増殖促進剤
JP2009256269A (ja) * 2008-04-18 2009-11-05 Tsumura Lifescience Co Ltd プロフィラグリン及び／又はフィラグリン産生促進剤
KR101483440B1 (ko) * 2008-05-02 2015-01-19 (주)아모레퍼시픽 포제를 활용한 약용식물 추출물 및 이를 함유하는 피부외용제 조성물
WO2011061932A1 (fr) 2009-11-18 2011-05-26 株式会社ロッテ Promoteur de la synthèse de collagène et de céramide, et inhibiteur de la saccharification du collagène
JP7075298B2 (ja) * 2018-07-05 2022-05-25 株式会社ノエビア 皮膚外用剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358939A (ja) * 1989-07-27 1991-03-14 Toreede Uindo Kk 老化防止食品及びその製造法
JP2001192317A (ja) * 2000-01-06 2001-07-17 Shiseido Co Ltd マトリックスメタロプロテアーゼ阻害剤
WO2003000912A1 (fr) * 2001-06-22 2003-01-03 Indian Institute Of Technology Procede de preparation d'acide gallique par coculture
JP2003524653A (ja) * 2000-02-28 2003-08-19 ナチュラル レメディーズ プライヴェト リミテッド 抗アレルギー性を有する改良された薬草組成物およびその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0358939A (ja) * 1989-07-27 1991-03-14 Toreede Uindo Kk 老化防止食品及びその製造法
JP2001192317A (ja) * 2000-01-06 2001-07-17 Shiseido Co Ltd マトリックスメタロプロテアーゼ阻害剤
JP2003524653A (ja) * 2000-02-28 2003-08-19 ナチュラル レメディーズ プライヴェト リミテッド 抗アレルギー性を有する改良された薬草組成物およびその製造方法
WO2003000912A1 (fr) * 2001-06-22 2003-01-03 Indian Institute Of Technology Procede de preparation d'acide gallique par coculture

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100031346A1 (it) * 2021-12-14 2023-06-14 Giuliani Spa Composizione ad attivita’ antinvecchiamento della pelle
EP4197521A1 (fr) * 2021-12-14 2023-06-21 Giuliani S.p.A. Composition ayant une activité anti-vieillissement de la peau

Also Published As

Publication number Publication date
JP2006265120A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
KR100858575B1 (ko) 피부 외용제 및 그 제조 방법
JP4025546B2 (ja) 美肌剤、皮膚の抗老化剤、美白剤および皮膚外用剤
KR20030005252A (ko) 피부 외용제 및 미백제
JP4091825B2 (ja) 皮膚外用剤
JP2005220084A (ja) アセロラ種子抽出物含有組成物
JP4091824B2 (ja) 皮膚外用剤
US20090253794A1 (en) Fibroblast Activator, Collagen Production Promoter, Collagen Contraction Promoter, Hyaluronic Acid Production Promoter, ATP Production Promoter, Melanin Formation Inhibitor, and Agent for External Application to the Skin
JP2007210915A (ja) 皮膚外用剤
WO2006101119A1 (fr) Promoteur de synthese du collagene
JP5241054B2 (ja) コラーゲン合成促進用組成物
JP2002212087A (ja) 皮膚外用剤
JP3987793B2 (ja) 皮膚外用剤
JP2005263794A (ja) コラーゲン合成促進用組成物
JP2003063925A (ja) 皮膚外用剤
JP2001181198A (ja) 美肌剤、皮膚の抗老化剤、美白剤および皮膚外用剤
KR100981343B1 (ko) 모공 축소용 화장료 조성물
JP5226200B2 (ja) 硫酸化グリコサミノグリカン産生促進剤およびこれを含有する皮膚外用剤
JP2009256269A (ja) プロフィラグリン及び／又はフィラグリン産生促進剤
JP4713032B2 (ja) 皮膚外用剤
JP4203325B2 (ja) 皮膚外用剤及び皮膚外用剤組成物
JP2010150173A (ja) 美白剤、メラニン産生抑制剤、及び美白用皮膚外用剤
JP2002275081A (ja) 皮膚外用剤
JP2009256326A (ja) 美白剤、及び皮膚外用剤
JP2009249366A (ja) コラーゲン産生促進剤、及び老化防止用皮膚外用剤
KR100714172B1 (ko) 주름 생성 억제 및 개선 효과를 갖는 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06729660

Country of ref document: EP

Kind code of ref document: A1